Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.10.3322/caac.21442Search in Google Scholar

[2] Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen L, Copeland L, et al. Ovarian cancer, version 2.2013. J Natl Compr Cancer Netw. 2013;11:1199–209.10.6004/jnccn.2013.0142Search in Google Scholar

[3] Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-SSearch in Google Scholar

[4] Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High volume intraperitoneal chemotherapy (“belly Bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978;1:161–6.10.1007/BF00253116Search in Google Scholar

[5] Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin – a Sankai Gynecology Study Group (SGSG) Study. Gynecol Oncol. 2005;99:591–6.10.1016/j.ygyno.2005.06.055Search in Google Scholar

[6] Flessner MF, Dedrick RL, Rippe B. Estimation of lymphatic absorption and intraperitoneal volume during hypertonic peritoneal dialysis. ASAIO Trans. 1989;35:178–81.10.1097/00002216-198904000-00016Search in Google Scholar

[7] Dedrick RL. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 1985;12(3 Suppl 4):1–6.Search in Google Scholar

[8] Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015;33:2841–7.10.1200/JCO.2015.61.4776Search in Google Scholar

[9] González-Moreno S, González-Bayón LA, Ortega-Pérez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2:68–75.10.4251/wjgo.v2.i2.68Search in Google Scholar

[10] Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–28.10.1016/S1470-2045(04)01425-1Search in Google Scholar

[11] Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254–61.10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-USearch in Google Scholar

[12] Panteix G, Beaujard A, Garbit F, Chaduiron-Faye C, Guillaumont M, Gilly F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res. 2002;22:1329–36.Search in Google Scholar

[13] van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34:148–54.10.1016/S0959-8049(97)00370-5Search in Google Scholar

[14] Ranieri G, Ferrari C, Di Palo A, Marech I, Porcelli M, Falagario G, et al. Bevacizumab-based chemotherapy combined with regional deep capacitive hyperthermia in metastatic cancer patients: a pilot study. Int J Mol Sci. 2017;18:1458.10.3390/ijms18071458Search in Google Scholar

[15] van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40.10.1056/NEJMoa1708618Search in Google Scholar

[16] Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;50:5790–4.Search in Google Scholar

[17] Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673–88.10.1016/S1055-3207(03)00034-6Search in Google Scholar

[18] Sun X, Li X-F, Russell J, Xing L, Urano M, Li GC, et al. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. Radiother Oncol. 2008;88:269–76.10.1016/j.radonc.2008.05.015Search in Google Scholar

[19] Petrillo M, De Iaco P, Cianci S, Perrone M, Costantini B, Ronsini C, et al. long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1660–5.10.1245/s10434-015-5050-xSearch in Google Scholar

[20] Roti Roti JL, Kampinga HH, Malyapa RS, Wright WD, vanderWaal RP, Xu M. Nuclear matrix as a target for hyperthermic killing of cancer cells. Cell Stress Chaperones. 1998;3:245–55.10.1379/1466-1268(1998)003<0245:NMAATF>2.3.CO;2Search in Google Scholar

[21] VanderWaal R, Thampy G, Wright WD, Roti Roti JL. Heat-induced modifications in the association of specific proteins with the nuclear matrix. Radiat Res. 1996;145:746–53.10.2307/3579366Search in Google Scholar

[22] El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia. 2004;6:117–27.10.1593/neo.03205Search in Google Scholar

[23] Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.10.1097/SLA.0b013e3181a45d86Search in Google Scholar

[24] Voron T, Eveno C, Jouvin I, Beaugerie A, Lo Dico R, Dagois S, et al. Cytoreductive surgery with a hyperthermic intraperitoneal chemotherapy program: safe after 40 cases, but only controlled after 140 cases. Eur J Surg Oncol. 2015;41:1671–7.10.1016/j.ejso.2015.09.005Search in Google Scholar PubMed

[25] Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014;149:170–5.10.1001/jamasurg.2013.3640Search in Google Scholar PubMed

[26] Jewell A, McMahon M, Khabele D. Heated intraperitoneal chemotherapy in the management of advanced ovarian cancer. Cancers. 2018;10:296.10.3390/cancers10090296Search in Google Scholar PubMed PubMed Central

[27] Ferron G, Simon L, Guyon F, Glehen O, Goere D, Elias D, et al. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. Eur J Surg Oncol. 2015;41:1361–7.10.1016/j.ejso.2015.07.012Search in Google Scholar PubMed

[28] Hotouras A, Desai D, Bhan C, Murphy J, Lampe B, Sugarbaker PH. Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review. Int J Gynecol Cancer. 2016;26:661–70.10.1097/IGC.0000000000000664Search in Google Scholar PubMed

[29] Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:1578–89.10.1016/j.ejso.2015.08.172Search in Google Scholar PubMed

[30] Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112:306–12.10.1038/bjc.2014.602Search in Google Scholar PubMed PubMed Central

[31] Cowan RA, O’Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia. 2017;33:548–53.10.1080/02656736.2017.1283066Search in Google Scholar PubMed PubMed Central

[32] Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V, et al. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series. Gynecol Oncol. 2014;132:303–6.10.1016/j.ygyno.2013.12.028Search in Google Scholar PubMed

[33] Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and american society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:3460–73.10.1200/JCO.2016.68.6907Search in Google Scholar PubMed PubMed Central

[34] Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, et al. Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. Bull Cancer (Paris). 2019;106:354–70.10.1016/j.bulcan.2019.01.014Search in Google Scholar PubMed

[35] Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a french multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–43.10.1016/j.ejso.2013.09.030Search in Google Scholar PubMed

[36] Cascales-Campos PA, Gil J, Gil E, Feliciangeli E, González-Gil A, Parrilla JJ, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC/IV ovarian cancer. Ann Surg Oncol. 2014;21:2383–9.10.1245/s10434-014-3599-4Search in Google Scholar PubMed

[37] Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106:193–200.10.1016/j.ygyno.2007.03.019Search in Google Scholar PubMed

[38] Zhang G, Zhu Y, Liu C, Chao G, Cui R, Zhang Z. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis. J Ovarian Res. 2019;12:33.10.1186/s13048-019-0509-1Search in Google Scholar PubMed PubMed Central

[39] Fagotti A, Costantini B, Petrillo M, Vizzielli G, Fanfani F, Margariti PA, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127:502–5.10.1016/j.ygyno.2012.09.020Search in Google Scholar PubMed

[40] Le Brun J-F, Campion L, Berton-Rigaud D, Lorimier G, Marchal F, Ferron G, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control study. Ann Surg Oncol. 2014;21:3621–7.10.1245/s10434-014-3693-7Search in Google Scholar PubMed

[41] Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, Asencio JM, Alvarez de Sierra P, Atahualpa Arenas F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol. 2013;39:1109–15.10.1016/j.ejso.2013.06.022Search in Google Scholar PubMed

[42] Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–5.10.1245/s10434-014-4157-9Search in Google Scholar PubMed

[43] Polom K, Roviello G, Generali D, Marano L, Petrioli R, Marsili S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. Int J Hyperthermia. 2016;32:298–310.10.3109/02656736.2016.1149233Search in Google Scholar PubMed

[44] Warschkow R, Tarantino I, Lange J, Müller SA, Schmied BM, Zünd M, et al. Does hyperthermic intraoperative chemotherapy lead to improved outcomes in patients with ovarian cancer? A single center cohort study in 111 consecutive patients. Patient Saf Surg. 2012;6:12.10.1186/1754-9493-6-12Search in Google Scholar PubMed PubMed Central

[45] Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004;94:325–32.10.1016/j.ygyno.2004.05.044Search in Google Scholar PubMed

[46] Gori J, Castaño R, Toziano M, Häbich D, Staringer J, De Quirós DG, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer. 2005;15:233–9.10.1136/ijgc-00009577-200503000-00008Search in Google Scholar

[47] Muñoz-Casares FC, Rufián S, Rubio MJ, Díaz CJ, Díaz R, Casado A, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753–9.10.1007/s12094-009-0438-3Search in Google Scholar PubMed

[48] Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101:149–55.10.1002/jso.21448Search in Google Scholar PubMed

[49] Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study. J Surg Oncol. 2014;110:661–5.10.1002/jso.23688Search in Google Scholar PubMed

[50] Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV, Mori KM, Lopez KL, et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol. 2017;80:405–10.10.1007/s00280-017-3376-8Search in Google Scholar PubMed

[51] Baiocchi G, Ferreira FO, Mantoan H, da Costa AA, Faloppa CC, Kumagai LY, et al. Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: a single-center comparative analysis. Ann Surg Oncol. 2016;23:1294–301.10.1245/s10434-015-4991-4Search in Google Scholar PubMed

[52] Chan JK, Herzog TJ, Hu L, Monk BJ, Kiet T, Blansit K, et al. Bevacizumab in treatment of high-risk ovarian cancer – a cost-effectiveness analysis. Oncologist. 2014;19:523–7.10.1634/theoncologist.2013-0322Search in Google Scholar PubMed PubMed Central

[53] Cohn DE, Kim KH, Resnick KE, O’Malley DM, Straughn JM. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol. 2011;29:1247–51.10.1200/JCO.2010.32.1075Search in Google Scholar PubMed